Thursday, August 16, 2018
 
 
 

 
TUCSON, Ariz., Aug. 16, 2018 /PRNewswire/ -- The Alzheimer's Research and Prevention Foundation (ARPF) will host its second Brain Longevity® Therapy Training on October 12-14 at American University  [READ MORE]
LONDON, August 16, 2018 /PRNewswire/ -- The growing healthcare expenditure and rising disposable income of people are expected to lead to an expansion in the applications of disposable negative pressure wound therapy (NPWT) devices across the globe. Developing countries are expected to provide substantial prospects for market.....   [READ MORE]
 
NEW YORK, Aug. 16, 2018 /PRNewswire/ -- Elysium Health, Inc.,™ a life sciences company developing clinically validated health products based on aging research, has entered into an exclusive license agreement with Mayo Clinic and Harvard University to use nicotinamide riboside for dietary supplement.....   [READ MORE]
 
DENVER, Aug. 16, 2018 /PRNewswire/ -- DuraScience Institute of USA, an advanced research and development institute headquartered in Denver Colorado, today announced its official launch to provide a series of innovative wellness solutions resulting from extensiv.....   [READ MORE]
 
DUBLIN, Aug 16, 2018 /PRNewswire/ --   [READ MORE]
 
 
MORE NEWS
 
 
 
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  • Citius Pharmaceuticals Successfully Raises $10 Million
  •  
     
     
     
     
     





    About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines